http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109420162-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y201-01043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109420162-B |
| titleOfInvention | Use of nuclear receptor binding domain protein 3 for combating viral infections |
| abstract | The present application relates to the use of nuclear receptor binding domain protein 3 in combating viral infections. In particular, it relates to the use of the nuclear receptor binding domain protein 3 for the preparation of a medicament for the treatment of a viral infection, said virus being selected from the group consisting of an RNA virus and a DNA virus. By the method, the replication of the virus can be reduced, the titer of the virus can be reduced, the survival of a subject can be improved, and the expression level of the type I interferon can be improved. The application also relates to the use of an agent targeting nuclear receptor binding domain protein 3 in the preparation of animal models of viral infection. The animal model exhibits reduced antiviral ability, increased viral replication, increased viral titer, reduced expression levels of type i interferon, and reduced survival compared to control animals. The application can realize the regulation and control of the effect of the type I interferon on treating the virus infection, and provides a new target for the prevention and treatment of the virus infection and related diseases. |
| priorityDate | 2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 195.